Favorable Response to CD34+ Cell Therapy Is Associated with a Decrease of Galectin-3 Levels in Patients with Chronic Heart Failure

Figure 2

Comparison of plasma galectin-3 level changes between responders and demonstrated that galectin-3 serum levels decreased in responders but increased in nonresponders at 3-month follow-up. Furthermore, LVEF did not change significantly in nonresponders but increased significantly in responders.